ClinicalTrials.gg
CompletedNCT02738632Updated Nov 25, 2016

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

A Phase 3 interventional study of Telmisartan/Amlodipine+Hydrochlorothiazide and Telmisartan/Amlodipine in Essential Hypertension, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-11-25.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Planned enrollment
18th of 34
300 · median 314
Started
2015
with 1 other
Phase 3
18 of 34
none open now
Registered
21st of 34
by date

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 18th largest by planned enrollment, is one of 2 that started in 2015, is one of 18 in phase 3, and was the 21st registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with Telmisartan/Amlodipine Combination for Essential Hypertension Patients not Controlled by Telmisartan/Amlodipine Combination

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 years old or above Koreans living in Korea
  2. Patients with uncontrolled essential hypertension at screening time(Visit 1)

    • Naïve: 160 mmHg ≤ sitSBP \< 200 mmHg
    • Use antihypertensive drugs:140 mmHg ≤ sitSBP \< 200 mmHg
  3. Patients with uncontrolled hypertension after Telmisartan/Amlodipine 40/5mg treatment for 6 weeks at randomization(Visit 2)

    • 140 mmHg ≤ sitSBP \< 200 mmHg
  4. Patients who agreed to participate in the trial

Exclusion criteria

Exclusion Criteria:

  1. Test results showing the following values at screening time(Visit 1)

    • The change of mean sitSBP ≥ 20 mmHg or sitDBP ≥ 10 mmHg on target arm between 1st and 2nd measurement
    • screening time(Visit 1), time of randomization(Visit 2): sitDBP ≥ 120 mmHg
  2. Patients with secondary blood pressure or suspected of secondary blood pressure (for example,aortic coarctation, primary aldosteronism, renal artery stenosis, pheochromocytoma)
  3. -Patients with congestive heart failure( class III\~IV)

    • Patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry
    • Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or arrhythmia
  4. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry
  5. Type I Diabets Mellitus or Type II Diabetes Mellitus with > 9%
  6. Patients who have history of severe or malignant retinopathy within 6 months prior to study entry
  7. Patients who suspected of Renal dysfunction that may affect the absorption, distribution, metabolism or excretion (Serum Creatinine :> 2mg/dL ), gastrointestinal, haematological, liver disease ( or ALT > 2.5 times of )
  8. Patients who should be administered antihypertensive drugs other than clinical trial medication(Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators)
  9. Patients who should be administered medications prohibited for concomitant use during study period
  10. Patients who are dependent on drugs or alcohol
  11. Patients with surgical and medical disease that may affect the absorption, distribution, metabolism or excretion
  12. Patients with to the components of drug.
  13. Patients with hypersensitivity to Sulfonamide
  14. Patients with anuria
  15. Patients with hypercalcemia, hyponatremia/hypokalemia
  16. Patients with Addison's disease
  17. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  18. Patients with any chronic or accute inflammation disease needed to chronic inflammation therapy
  19. History of malignant tumor including leukemia, lymphoma within 5 years
  20. Patients taking other clinical trial drugs within 30 days from the time of visit for screening
  21. Pregnancy, breast-feeding, or Patients
  22. Patients who are judged unsuitable to participate in this study by investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Telmisartan/Amlodipine+Hydrochlorothiazide

    Telmisartan/Amlodipine combination drug and Hydrochlorothiazide

    Drug: Telmisartan/Amlodipine+Hydrochlorothiazide

  • Active comparator
    Telmisartan/Amlodipine

    Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide

    Drug: Telmisartan/Amlodipine · Drug: Placebo for Hydrochlorothiazide

Interventions

  • DrugTelmisartan/Amlodipine+Hydrochlorothiazide

    Drug pages: Telmisartan · Amlodipine · Hydrochlorothiazide

    Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD

  • DrugTelmisartan/Amlodipine

    Drug pages: Telmisartan · Amlodipine

    Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD

  • DrugPlacebo for Hydrochlorothiazide
06

What researchers measure

Primary outcomes

  1. The change of sitting systolic blood pressure

    Time frame: From baseline at week 8

Secondary outcomes

  1. The change of sitting systolic blood pressure

    Time frame: From baseline at week 2

  2. The change of sitting diastolic blood pressure

    Time frame: From baseline at week 2 and 8

  3. The ratio of subjects who get normalized blood pressure

    Time frame: at week 2 and 8

  4. Response Rate

    Time frame: at week 2 and 8

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Sung KC, Oh YS, Cha DH, Hong SJ, Won KH, Yoo KD, Rha SW, Ahn YK, Ahn JC, Jang JY, Hong TJ, Cho SK, Park SH, Hyon MS, Nam CW, Chae IH, Yoo BS, Song JM, Jeong JO, Yoon YW, Kim BS, Yang TH, Cho DK, Kim SH, Choi YJ, Ahn JH, Jeon DW, Kim HS. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study. Clin Ther. 2018 Jan;40(1):50-63.e3. doi: 10.1016/j.clinthera.2017.11.006. Epub 2017 Dec 14. PubMed 29248384 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
Apr 14, 2016
Start
May 2015
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Nov 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02738632
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
May 2015
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Nov 25, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Hydrochlorothiazide

Start the discussion